156 related articles for article (PubMed ID: 38238578)
21. Enrollment in clinical trials correlates with improved survival in metastatic melanoma.
Seetharamu N; Tu TJ; Christos P; Ott PA; Berman RS; Shapiro RL; Osman I; Pavlick AC
Oncology; 2011; 81(5-6):403-9. PubMed ID: 22270052
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors.
Looman EL; Cheng PF; Lai-Kwon J; Morgan L; Wakkee M; Dummer R; Dimitriou F
Cancer Med; 2023 Jun; 12(11):12861-12873. PubMed ID: 37119050
[TBL] [Abstract][Full Text] [Related]
23. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
24. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
26. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
27. Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE).
Lai-Kwon J; Kelly B; Lane S; Biviano R; Bartula I; Brennan F; Kivikoski I; Thompson J; Dhillon HM; Menzies A; Long GV
Support Care Cancer; 2022 Nov; 30(11):9587-9596. PubMed ID: 36136246
[TBL] [Abstract][Full Text] [Related]
28. Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
Kamminga NCW; van der Veldt AAM; Joosen MCW; de Joode K; Joosse A; Grünhagen DJ; Nijsten TEC; Wakkee M; Lugtenberg M
Br J Dermatol; 2022 Sep; 187(3):381-391. PubMed ID: 35596713
[TBL] [Abstract][Full Text] [Related]
29. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
[TBL] [Abstract][Full Text] [Related]
30. Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications.
Mandel VD; Medri M; Manganoni AM; Pavoni L; De Rosa F; Ribero S; Foca F; Andreis D; Mazzoni L; Magi S; Farnetani F; Palla M; Ulivi P; Stanganelli I
J Dermatolog Treat; 2022 May; 33(3):1368-1375. PubMed ID: 32875931
[TBL] [Abstract][Full Text] [Related]
31. Successes and limitations of targeted cancer therapy in melanoma.
Romano E; Michielin O
Prog Tumor Res; 2014; 41():78-88. PubMed ID: 24727988
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
35. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
[TBL] [Abstract][Full Text] [Related]
36. The impact of effective systemic therapies on surgery for stage IV melanoma.
Smith MJF; Smith HG; Joshi K; Gore M; Strauss DC; Hayes AJ; Larkin J
Eur J Cancer; 2018 Nov; 103():24-31. PubMed ID: 30196107
[TBL] [Abstract][Full Text] [Related]
37. The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Dummer R; Welti M; Ramelyte E
J Transl Med; 2023 Aug; 21(1):529. PubMed ID: 37543586
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma.
Howell AV; Gebregziabher M; Thiers BH; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
J Geriatr Oncol; 2021 Apr; 12(3):394-401. PubMed ID: 33132048
[TBL] [Abstract][Full Text] [Related]
39. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes.
Wasif N; Bagaria SP; Ray P; Morton DL
J Surg Oncol; 2011 Aug; 104(2):111-5. PubMed ID: 21381040
[TBL] [Abstract][Full Text] [Related]
40. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors.
Mamoor M; Postow MA; Lavery JA; Baxi SS; Khan N; Mao JJ; Rogak LJ; Sidlow R; Thom B; Wolchok JA; Korenstein D
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
